{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:27:35Z","timestamp":1790162855334,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1000967"],"award-info":[{"award-number":["1000967"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1063476"],"award-info":[{"award-number":["1063476"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003550","name":"Queensland Government","doi-asserted-by":"publisher","award":["1117061"],"award-info":[{"award-number":["1117061"]}],"id":[{"id":"10.13039\/501100003550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001792","name":"James Cook University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008451","name":"College of Medicine and Dentistry, James Cook University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008451","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvascsurg.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular Surgery"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jvs.2020.08.129","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T11:37:16Z","timestamp":1599133036000},"page":"1396-1403.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["The cost-effectiveness of intensive low-density lipoprotein cholesterol lowering in people with peripheral artery disease"],"prefix":"10.1016","volume":"73","author":[{"given":"Domenico R.","family":"Nastasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph V.","family":"Moxon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Norman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra F.","family":"Trollope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Rowbotham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Quigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5779-8848","authenticated-orcid":false,"given":"Jonathan","family":"Golledge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvs.2020.08.129_bib1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2020.08.129_bib2","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1016\/j.atherosclerosis.2008.10.023","article-title":"Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry","volume":"204","author":"Cacoub","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jvs.2020.08.129_bib3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jvs.2006.12.054","article-title":"Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions","volume":"45","year":"2007","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2020.08.129_bib4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijcard.2018.04.122","article-title":"The cost-effectiveness of PCSK9 inhibitors\u2014the Australian healthcare perspective","volume":"267","author":"Kumar","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jvs.2020.08.129_bib5","doi-asserted-by":"crossref","first-page":"e010007","DOI":"10.1161\/JAHA.118.010007","article-title":"Eligibility, clinical outcomes, and budget impact of PCSK9 inhibitor adoption: the CANHEART PCSK9 study","volume":"7","author":"Ko","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jvs.2020.08.129_bib6","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jvs.2016.03.429","article-title":"Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization","volume":"64","author":"Sigvant","year":"2016","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2020.08.129_bib7","first-page":"e002305","article-title":"High-intensity statin therapy is associated with improved survival in patients with peripheral artery disease","volume":"6","author":"Foley","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jvs.2020.08.129_bib8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jvs.2020.08.129_bib9","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.amjcard.2009.10.067","article-title":"Relation of infra-renal abdominal aortic calcific deposits and cardiovascular events in patients with peripheral artery disease","volume":"105","author":"Parr","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jvs.2020.08.129_bib10","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.atherosclerosis.2007.06.027","article-title":"Relationship between CT anthropometric measurements, adipokines and abdominal aortic calcification","volume":"197","author":"Golledge","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jvs.2020.08.129_bib11","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol","volume":"73","author":"Grundy","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jvs.2020.08.129_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jvs.2020.08.129_bib13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.atherosclerosis.2013.04.030","article-title":"Body mass index is inversely associated with mortality in patients with peripheral vascular disease","volume":"229","author":"Golledge","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jvs.2020.08.129_bib14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jvs.2006.09.006","article-title":"Association of obesity and metabolic syndrome with the severity and outcome of intermittent claudication","volume":"45","author":"Golledge","year":"2007","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2020.08.129_bib15","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jvs.2020.08.129_bib16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1373\/clinchem.2017.279422","article-title":"Imputation of baseline LDL cholesterol concentration in patients with familial hypercholesterolemia on statins or ezetimibe","volume":"64","author":"Ruel","year":"2018","journal-title":"Clin Chem"},{"key":"10.1016\/j.jvs.2020.08.129_bib17","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1002\/bjs.10460","article-title":"Assessment and validation of a novel angiographic scoring system for peripheral artery disease","volume":"104","author":"Morris","year":"2017","journal-title":"Brit J Surg"},{"key":"10.1016\/j.jvs.2020.08.129_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.atherosclerosis.2017.06.925","article-title":"Baseline serum phosphatidylcholine plasmalogen concentrations are inversely associated with incident myocardial infarction in patients with mixed peripheral artery disease presentations","volume":"263","author":"Moxon","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jvs.2020.08.129_bib20","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/00005650-199111000-00007","article-title":"Functional status versus utilities in survivors of myocardial infarction","volume":"29","author":"Tsevat","year":"1991","journal-title":"Med Care"},{"key":"10.1016\/j.jvs.2020.08.129_bib21","doi-asserted-by":"crossref","first-page":"e011322","DOI":"10.1161\/JAHA.118.011322","article-title":"Acute and 1-year hospitalization costs for acute myocardial infarction treated with percutaneous coronary intervention: results from the TRANSLATE-ACS registry","volume":"8","author":"Cowper","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jvs.2020.08.129_bib22","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1186\/1471-2458-12-398","article-title":"Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study","volume":"12","author":"Cobiac","year":"2012","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jvs.2020.08.129_bib23","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1161\/01.STR.0000040407.44712.C7","article-title":"Brief comprehensive quality of life assessment after stroke: the assessment of quality of life instrument in the North East Melbourne Stroke Incidence Study (NEMESIS)","volume":"33","author":"Sturm","year":"2002","journal-title":"Stroke"},{"key":"10.1016\/j.jvs.2020.08.129_bib24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/CEOR.S95662","article-title":"Short- and longer-term health-care resource utilization and costs associated with acute ischemic stroke","volume":"8","author":"Johnson","year":"2016","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.jvs.2020.08.129_bib25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.1995.03530020083037","article-title":"Revascularization for femoropopliteal disease: a decision and cost-effectiveness analysis","volume":"274","author":"Hunink","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.jvs.2020.08.129_bib26","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.apmr.2004.06.072","article-title":"Reamputation, mortality, and health care costs among persons with dysvascular lower-limb amputations","volume":"86","author":"Dillingham","year":"2005","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.jvs.2020.08.129_bib27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/dme.12647","article-title":"The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84)","volume":"32","author":"Alva","year":"2015","journal-title":"Diabetic Med"},{"key":"10.1016\/j.jvs.2020.08.129_bib28","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1177\/1526602818774786","article-title":"Cost Analysis of initial treatment with endovascular revascularization, open surgery, or primary major amputation in patients with peripheral artery disease","volume":"25","author":"Tang","year":"2018","journal-title":"J\u00a0Endovasc Ther"},{"key":"10.1016\/j.jvs.2020.08.129_bib29","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0741-5214(94)70036-2","article-title":"Hospital costs of revascularization procedures for femoropopliteal arterial disease","volume":"19","author":"Hunink","year":"1994","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2020.08.129_bib31","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00005650-200006000-00004","article-title":"One thousand health-related quality-of-life estimates","volume":"38","author":"Tengs","year":"2000","journal-title":"Med Care"},{"key":"10.1016\/j.jvs.2020.08.129_bib32","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1524-4733.2004.74002.x","article-title":"Discounting health outcomes in economic evaluation: the ongoing debate","volume":"7","author":"Severens","year":"2004","journal-title":"Value Health"},{"key":"10.1016\/j.jvs.2020.08.129_bib33","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost-effectiveness of interventions: alternative approaches","volume":"93","author":"Marseille","year":"2015","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jvs.2020.08.129_bib35","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.amjcard.2011.01.052","article-title":"Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations","volume":"107","author":"Pittman","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jvs.2020.08.129_bib36","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2017.05.018","article-title":"Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: a real-world evidence study in primary care","volume":"263","author":"Guglielmi","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jvs.2020.08.129_bib37","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.2147\/PPA.S149423","article-title":"Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemia","volume":"12","author":"Kosmas","year":"2018","journal-title":"Patient Prefer Adher"},{"key":"10.1016\/j.jvs.2020.08.129_bib38","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/clc.22713","article-title":"PCSK9 inhibitor access barriers\u2014issues and recommendations: Improving the access process for patients, clinicians and payers","volume":"40","author":"Baum","year":"2017","journal-title":"Clin Cardiol"}],"container-title":["Journal of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521420320152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521420320152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:26:19Z","timestamp":1777573579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0741521420320152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0741521420320152"],"URL":"https:\/\/doi.org\/10.1016\/j.jvs.2020.08.129","relation":{},"ISSN":["0741-5214"],"issn-type":[{"value":"0741-5214","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cost-effectiveness of intensive low-density lipoprotein cholesterol lowering in people with peripheral artery disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvs.2020.08.129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc. on behalf of the Society for Vascular Surgery.","name":"copyright","label":"Copyright"}]}}